

#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

ART UNIT

1624

# NOTICE OF ALLOWANCE AND FEE(S) DUE

7590

06/17/2002

RONALD L GRUDZIECKI BURNS DOANE SWECKER & MATHIS PO BOX 1404 ALEXANDRIA, VA 223131404 EXAMINÉR
TRUONG, TAMTHOM NGO

11.001.0, 11.11.10.11.100

CLASS-SUBCLASS

544-058100

DATE MAILED: 06/17/2002

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/424.059 11/18/1999 YOICHI NUNOKAWA 001560-376 7507

TITLE OF INVENTION: NF-KB INHIBITOR COMPRISING PHENYLMETHYL BENZOQUINONE AS THE ACTIVE INGREDIENT

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1280	\$0	\$1280	09/17/2002

THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. <u>PROSECUTION ON THE MERITS IS CLOSED.</u> THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.

THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE REFLECTS A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE APPLIED IN THIS APPLICATION. THE PTOL-85B (OR AN EQUIVALENT) MUST BE RETURNED WITHIN THIS PERIOD EVEN IF NO FEE IS DUE OR THE APPLICATION WILL BE REGARDED AS ABANDONED.

#### HOW TO REPLY TO THIS NOTICE:

I. Review the SMALL ENTITY status shown above. If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is changed, pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above and notify the United States Patent and Trademark Office of the change in status, or

B. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check the box below and enclose the PUBLICATION FEE and 1/2 the ISSUE FEE shown above.

 Applicant claims SMALL ENTITY status. See 37 CFR 1.27.

II. PART B - FEE(S) TRANSMITTAL should be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). Even if the fee(s) have already been paid, Part B - Fee(s) Transmittal should be completed and returned. If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Box ISSUE FEE unless advised to the contrary.

IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.

#### PART B - FEE(S) TRANSMITTAL

# Complete and send this form, together with applicable fee(s), to: Mail Box ISSUE FEE

**Commissioner for Patents** Washington, D.C. 20231

(703)746-4000 <u>Fax</u>

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 4 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CURRESPONDENCE ADDRESS (Note: Legibly mark-up with any corrections or use Block I

06/17/2002

RONALD L GRUDZIECKI **BURNS DOANE SWECKER & MATHIS** PO BOX 1404 ALEXANDRIA, VA 223131404

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

Certificate of Mailing or Transmission

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail; in an envelope addressed to the Box Issue Fee address above, or being facsimile transmitted to the USPTO, on the date indicated below.

ansimited to the ODI 10, on the tale marcated ceron.	
	(Depositor's name
	(Signature
	(Date

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/424 059	11/18/1999	YOICHI NUNOKAWA	001560-376	7507

TITLE OF INVENTION: NF-KB INHIBITOR COMPRISING PHENYLMETHYL BENZOQUINONE AS THE ACTIVE INGREDIENT

APPLN. TYPE	SMALL ENTITY	ISSUE FEE	PUBLICATION FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1280	\$0	\$1280	09/17/2002
EXAMI TRUONG, TAM		ART UNIT	CLASS-SUBCLASS 544-058100		
1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).  Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47) attached. Use of a Customer Number is required.		2. For printing on the patent of the names of up to 3 registere or agents OR, alternatively, (single firm (having as a meattorney or agent) and the n registered patent attorneys or a is listed, no name will be printed.	d patent attorneys 2) the name of a mber a registered names of up to 2 agents. If no name		

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. Inclusion of assignee data is only appropriate when an assignment has been previously submitted to the USPTO or is being submitted under separate cover. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

			•		
Please check the appropriate assignee category or categories (will not b	e printed on the patent)	🗅 individual	☐ corporation or other private	group entity	☐ government
la. The following fee(s) are enclosed:	4b. Payment of Fee(s):				
☐ Issue Fee	A check in the amount	of the fee(s) is en	closed.		
□ Publication Fee	Payment by credit care	d. Form PTO-2038	is attached.		
☐ Advance Order - # of Copies	☐ The Commissioner is Deposit Account Number	nereby authorized	by charge the required fee(s), or (enclose an extra copy of this	credit any ov s form).	erpayment, to
Commissioner for Patents is requested to apply the Issue Fee and Publi	cation Fee (if any) or to re	-apply any previo	usly paid issue fee to the applica	ation identified	d above.
Authorized Signature) (Date)					
NOTE; The Issue Fee and Publication Fee (if required) will not be other than the applicant; a registered attorney or agent; or the assinterest as shown by the records of the United States Patent and Trade	signee or other party in				
This collection of information is required by 37 CFR 1.311. The in obtain or retain a benefit by the public which is to file (and by the application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFl estimated to take 12 minutes to complete, including gathering, prepa completed application form to the USPTO. Time will vary depend case. Any comments on the amount of time you require to con suggestions for reducing this burden, should be sent to the Chief Ir Patent and Trademark Office, U.S. Department of Commerce, Wash NOT SEND FEES OR COMPLETED FORMS TO THIS A Commissioner for Patents, Washington, DC 20231.	iring, and submitting the ling upon the individual neglete this form and/ornformation Officer, U.S. ington, D.C. 20231. DO				

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



#### United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

	APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
	09/424,059	11/18/1999	YOICHI NUNOKAWA <sup>;</sup>	001560-376	7507	
	*	7590 06/17/2002	ê T	EXAMINI	ER	
RONALD L GRUDZIECKI BURNS DOANE SWECKER & MATHIS			E	TRUONG, TAMTHOM NGO		
	PO BOX 1404	SWECKER & MATHIS		ART UNIT	PAPER NUMBER	
	ALEXANDRIA,	VA 223131404	and the state of t	1624		
	<b>:</b>		<b>‡</b>	DATE MAILED: 06/17/2002		

# Determination of Patent Term Extension under 35 U.S.C. 154 (b) (application filed after June 7, 1995 but prior to May 29, 2000)

The patent term extension is 0 days. Any patent to issue from the above identified application will include an indication of the 0 day extension on the front page.

If a continued prosecution application (CPA) was filed in the above-identified application, the filing date that determines patent term extension is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) system. (http://pair.uspto.gov)

·	Application No.	Applicant(s)				
	09/424,059	NUNOKAWA ET AL.				
Notice of Allowability	Examiner	Art Unit				
	Tamthom N. Truong	1624				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.						
1. This communication is responsive to <u>amendment of 3-25-C</u>	<u>02</u> .	*				
<ul> <li>2.  The allowed claim(s) is/are 2-13, 15, 17-28, and 38-41</li> <li>3.  The drawings filed on are accepted by the Examine</li> </ul>	 r	•				
	Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
Certified copies of the priority documents have						
2. Certified copies of the priority documents have						
3. ☑ Copies of the certified copies of the priority documents of the	cuments have been received in this r	national stage application from the				
* Certified copies not received:  5. Acknowledgment is made of a claim for domestic priority up	ndar 35 I I S.C. & 110(a) (to a provisi	onal application)				
(a) The translation of the foreign language provisional a		энагаррисацопу.				
6. Acknowledgment is made of a claim for domestic priority un						
Applicant has THREE MONTHS FROM THE "MAILING DATE" of below. Failure to timely comply will result in ABANDONMENT of	this communication to file a reply co	omplying with the requirements noted NTH PERIOD IS NOT EXTENDABLE.				
7. A SUBSTITUTE OATH OR DECLARATION must be subminFORMAL PATENT APPLICATION (PTO-152) which gives reas						
8.  CORRECTED DRAWINGS must be submitted.  (a) including changes required by the Notice of Draftspers.  1) hereto or 2) to Paper No						
	<ul> <li>(b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Examiner.</li> <li>(c) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No</li> </ul>					
(c)   Including changes required by the attached Examiner	s Amendment / Comment of in the C	Tince action of Paper No				
	Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the top margin (not the back) of each sheet. The drawings should be filed as a separate paper with a transmittal letter addressed to the Official Draftsperson.					
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.						
Attachment(s)						
<ul> <li>1 ☐ Notice of References Cited (PTO-892)</li> <li>3 ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>5 ☐ Information Disclosure Statements (PTO-1449), Paper No. 3.</li> <li>7 ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material</li> </ul>	4☐ Interview Summa 6⊠ Examiner's Amer	al Patent Application (PTO-152)  ary (PTO-413), Paper No  ndment/Comment  ement of Reasons for Allowance				

Application/Control Number: 09/424,059

Art Unit: 1624

#### **EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR

1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Cancel claims 42 and 43 without prejudice or disclaimer.

Claim 22: line 1, insert -40— after the word 'claim'.

Authorization for this examiner's amendment was given in a telephone interview with Ms. Mercedes Meyer on 6-14-02.

# Allowable Subject Matter

Applicant's amendment of 3-25-02 has overcome the previous rejections of 112/1<sup>st</sup> (Scope of Enablement) by deleting "prevention" from method claims. Thus, said rejection is withdrawn herein for the allowance of claims 2-13, 15, 17-28, and 38-41.

# Reasons for Allowance

The following is an examiner's statement of reasons for allowance:

The invention is drawn to methods of inhibiting NF-κB,

Application/Control Number: 09/424,059

Art Unit: 1624

and TNF-α using benzoquinone derivatives. The closest references, Suzuki et. al. and Nunokawa et. al., teaches benzoquinone derivatives. However, said references do not relate the inhibition of NF-κB and TNF-α to benzoquinone derivatives. Thus, there is no motivation for one skilled in the art to use benzoquinone derivatives as claimed herein.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Tamthom N. Truong whose telephone number is 703-305-4485. The examiner can normally be reached on M-F (9:00-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mukund Shah can be reached on 703-308-4716. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

ART UNIT 1624

T. Truong

June 14, 2002